When and How to Administer Oxytocin for Active Management of Third Stage of Labour

N/ACompletedNCT01954186

Etlik Zubeyde Hanim Womens' Health and Teaching Hospital600 enrolled

Overview

To compare the efficacy of the route and timing of oxytocin administration for Active management of third stage of labour (AMTSL).

Our objective is to determine the most efficient route and timing of oxytocin administration by measuring the duration of third stage of labour, quantitative blood during the first hour after delivery and comparing haemoglobin and haematocrit changes and the need for additional interventions in patients who had either a spontaneous labour or received labour augmentation with oxytocin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

SINGLE

Enrollment

600

Conditions

Postpartum Bleeding

Interventions

intravenous & intramuscular oxytocinDRUG

intravenous or intramuscular 10 iu oxytocin

after delivery of the fetus & when anterior shoulder seenPROCEDURE

oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * having a singleton pregnancy above 37th gestational week * normal live vaginal delivery with cephalic presentation * being in active labor Exclusion Criteria: * Fetal demise * multiple pregnancy * known coagulation disorder * presentation anomalies * placental pathology * liver disease * thrombocytopenia * hypertension or being currently on anticoagulants * having a cesarean section, operative delivery or deep vaginal tear * chorioamnionitis * developing HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) or DIC (disseminated intravascular coagulation) before delivery

Locations (1)

Etlik Zübeyde Hanım Women's Health Teaching and Research Hospital

Ankara, Turkey (Türkiye)

Outcomes

Primary Outcomes

postpartum bleeding in the third stage of labour

Time frame: participants will be followed for the duration of hospital stay, an expected average of 48 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.